Can a Cure for HIV Be Achieved? Exploring the Prospects of HIV Treatment in the Future
Since the first reported cases of HIV in 1981, the global fight against the virus has seen significant advancements, particularly since 2008. While a definitive, widely applicable cure remains elusive, progress has been incremental and marked by several remarkable milestones.
Rare but Confirmed Cures via Stem-Cell Transplantation
One of the most significant milestones came in 2008 when the "Berlin Patient" was functionally cured of HIV after receiving a stem-cell transplant from a donor with a CCR5 mutation. Since then, seven documented cases of HIV cures via stem-cell transplantation have been reported, the latest in 2024 in Germany. These procedures, while rare and complex, offer proof that a cure is possible in principle.
Approval of Revolutionary Twice-Yearly Injectable PrEP
In 2025, the FDA approved lenacapavir (Yeztugo), a twice-yearly injectable pre-exposure prophylaxis (PrEP) with near 100% efficacy in preventing HIV infection. This breakthrough could dramatically reduce new infections by improving adherence through less frequent dosing.
Emerging Gene-Editing Therapies in Trials
CRISPR-based therapies, such as EBT-101, which entered clinical trials around 2022-2024, aim to excise or inactivate HIV DNA hidden in latent reservoirs. Initial results from the phase 1/2 trials of EBT-101 confirmed that the therapy was well tolerated, but its impact on the virus was more limited, with all participants who paused antiretroviral therapy experiencing viral rebound.
Continuous Evolution and Refinement of ART Regimens
Since the 1990s, antiretroviral therapy (ART) has been transformative but remains a lifelong treatment due to viral reservoirs. Recent developments include combination pills, integrase inhibitors, and long-acting injectables like Cabenuva, which improve patient adherence and reduce side effects but do not eliminate the virus.
However, a scalable, safe, and widely applicable cure remains an unmet goal. Research continues on multiple fronts, moving slowly from laboratory breakthroughs to clinical reality. UNAIDS warned in May that it may be forced to lay off more than half its workforce due to reduced contributions from major players, potentially stalling the reach of even the most promising innovations.
[1] AIDSmap. (2023). EBT-101: A CRISPR-based HIV Cure Therapy. [online] Available at: https://www.aidsmap.com/EBT-101/page/2714636
[2] FDA. (2025). FDA Approves Lenacapavir (Yeztugo) for the Prevention of HIV Infection. [online] Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-lenacapavir-yeztugo-prevention-hiv-infection
[3] UNAIDS. (2025). UNAIDS Warns of Potential Layoffs Due to Reduced Contributions from Major Players. [online] Available at: https://unaids.org/en/resources/presscentre/featurestories/2025/may/unaids-warns-of-potential-layoffs-due-to-reduced-contributions-from-major-players
[4] The Lancet HIV. (2020). Safety and Efficacy of GS-1738, a Long-Acting, Injectable Formulation of the Integrase Strand Transfer Inhibitor GS-9803, for HIV Pre-exposure Prophylaxis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2b Study. [online] Available at: https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(20)30120-9/fulltext
- Biotech companies and scientists continue to push the boundaries of immunotherapy and gene-editing in clinical trials, such as the CRISPR-based therapy EBT-101, aiming to eradicate HIV as a medical-condition.
- The science of health-and-wellness has progressed significantly in the fight against HIV, with the FDA's approval of lenacapavir in 2025, a breakthrough injectable pre-exposure prophylaxis (PrEP) that offers nearly 100% efficacy in preventing HIV infection.
- Notable milestones in the global fight against HIV include the rare, but confirmed cures achieved via stem-cell transplantation, like the one that occurred in 2008 with the "Berlin Patient," demonstrating the potential for finding a permanent solution to the virus. However, a scalable, safe, and widely applicable cure remains an unmet goal, and challenges persist due to funding cuts in the medical field.
